{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:40:41Z","timestamp":1789501241671,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012359","name":"Promotion and Mutual Aid Corporation for Private Schools of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08549"],"award-info":[{"award-number":["20K08549"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.alit.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T11:28:34Z","timestamp":1687001314000},"page":"94-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics"],"prefix":"10.1016","volume":"73","author":[{"given":"Hitoshi","family":"Sasano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Takeshige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Ishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsutaro","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisaya","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Izuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2023.06.001_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2023.06.001_bib2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jaip.2018.03.008","article-title":"Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate-to-severe asthma","volume":"6","author":"Papi","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2023.06.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1081-1206(10)60826-5","article-title":"Asthma: a syndrome composed of heterogeneous diseases","volume":"101","author":"Borish","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib5","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2023.06.001_bib6","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1111\/all.13974","article-title":"Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D2 and cysteinyl leukotrienes in allergic rhinitis","volume":"74","author":"Tojima","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2023.06.001_bib7","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2023.06.001_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2023.06.001_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(00)00690-7","article-title":"Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone","volume":"406","author":"Zhang","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.alit.2023.06.001_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01167-2017","article-title":"Asthma and corticosteroids: time for a more precise approach to treatment","volume":"49","author":"Dunican","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2023.06.001_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.alit.2019.01.004","article-title":"Biological treatments for severe asthma: a major advance in asthma care","volume":"68","author":"Busse","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2023.06.001_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2023.06.001_bib13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2023.06.001_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nature01433","article-title":"Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1","volume":"422","author":"Treiner","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.alit.2023.06.001_bib19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3389\/fimmu.2018.01333","article-title":"Mucosal-associated invariant T cells in autoimmune diseases","volume":"9","author":"Chiba","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/intimm\/dxab070","article-title":"Characteristics of mucosal-associated invariant T cells and their roles in immune diseases","volume":"33","author":"Chiba","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Kjer-Nielsen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.alit.2023.06.001_bib22","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1371\/journal.pbio.1000054","article-title":"Stepwise development of MAIT cells in mouse and human","volume":"7","author":"Martin","year":"2009","journal-title":"Plos Biol"},{"key":"10.1016\/j.alit.2023.06.001_bib23","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1084\/jem.20130958","article-title":"Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells","volume":"210","author":"Reantragoon","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2023.06.001_bib24","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.alit.2023.06.001_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ni.1890","article-title":"Antimicrobial activity of mucosal-associated invariant T cells","volume":"11","author":"Le Bourhis","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/intimm\/dxr047","article-title":"Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis","volume":"23","author":"Miyazaki","year":"2011","journal-title":"Int Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.20142110","article-title":"Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers","volume":"212","author":"Rahimpour","year":"2015","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.alit.2023.06.001_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaci.2015.01.014","article-title":"Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms","volume":"136","author":"Hinks","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108606","article-title":"Changes in the phenotype and function of mucosal-associated invariant T cells in neutrophilic asthma","volume":"106","author":"Wen","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.alit.2023.06.001_bib30","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jaci.2019.12.891","article-title":"Mucosal-associated invariant T cells restrict allergic airway inflammation","volume":"145","author":"Ye","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-8570-8_23","article-title":"Mouse models of asthma","volume":"1809","author":"Gorska","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.alit.2023.06.001_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.alit.2016.07.005","article-title":"Circulating activated innate lymphoid cells and mucosal-associated invariant T cells are associated with airflow limitation in patients with asthma","volume":"66","author":"Ishimori","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2023.06.001_bib33","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available from: http:\/\/www.ginasthma.org\/. 2006."},{"key":"10.1016\/j.alit.2023.06.001_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12931-020-01543-5","article-title":"Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study","volume":"21","author":"Abdo","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2023.06.001_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.alit.2023.06.001_bib36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma - a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2023.06.001_bib37","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.alit.2023.06.001_bib38","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"Mummler","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2023.06.001_bib39","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/all.15382","article-title":"RELIght: a two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response","volume":"77","author":"Kallieri","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2023.06.001_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12931-021-01733-9","article-title":"Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics","volume":"22","author":"Liu","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2023.06.001_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib43","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","article-title":"Asthma outcomes: pulmonary physiology","volume":"129","author":"Tepper","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib44","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00059810","article-title":"Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias","volume":"37","author":"Okamoto","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2023.06.001_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature13160","article-title":"T-cell activation by transitory neo-antigens derived from distinct microbial pathways","volume":"509","author":"Corbett","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.alit.2023.06.001_bib46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/eji.202048645","article-title":"Interleukin-17 producing mucosal associated invariant T cells - emerging players in chronic inflammatory diseases?","volume":"50","author":"Pisarska","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib47","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.4049\/jimmunol.1402945","article-title":"Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity","volume":"194","author":"Carolan","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib48","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.4049\/jimmunol.1801600","article-title":"Obesity reduces mTORC1 activity in mucosal-associated invariant T cells, driving defective metabolic and functional responses","volume":"202","author":"O'Brien","year":"2019","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.4TA0815-391RR","article-title":"Human MAIT-cell responses to Escherichia coli: activation, cytokine production, proliferation, and cytotoxicity","volume":"100","author":"Dias","year":"2016","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.alit.2023.06.001_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/imr.12559","article-title":"Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation","volume":"278","author":"Kimura","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.alit.2023.06.001_bib51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201cSuper-Responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.alit.2023.06.001_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2019.02.004","article-title":"Severe asthma in Japan","volume":"68","author":"Nagase","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2023.06.001_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2023.06.001_bib54","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/all.13879","article-title":"Mepolizumab does not alter the blood basophil count in severe asthma","volume":"74","author":"Wright","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2023.06.001_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2332\/allergolint.13-RAI-0678","article-title":"Serum periostin: a novel biomarker for asthma management","volume":"63","author":"Matsumoto","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2023.06.001_bib56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2023.06.001_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2023.06.001_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-018-0968-8","article-title":"Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases","volume":"20","author":"Sridhar","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.alit.2023.06.001_bib59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex\u00a0vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib60","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.4049\/jimmunol.173.10.6418","article-title":"CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation","volume":"173","author":"Dalbeth","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2013-11-536888","article-title":"Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease","volume":"124","author":"Munneke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.alit.2023.06.001_bib62","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/eji.201344160","article-title":"CD8(+) MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis","volume":"44","author":"Willing","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib63","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3389\/fimmu.2019.02681","article-title":"A\u00a0critical role for mucosal-associated invariant T cells as regulators and therapeutic targets in systemic lupus erythematosus","volume":"10","author":"Murayama","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2023.06.001_bib64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jcmgh.2021.08.018","article-title":"Activated mucosal-associated invariant T cells have a pathogenic role in a murine model of inflammatory bowel disease","volume":"13","author":"Yasutomi","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.alit.2023.06.001_bib65","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1370","article-title":"Invariant V(alpha)19i T cells regulate autoimmune inflammation","volume":"7","author":"Croxford","year":"2006","journal-title":"Nat Immunol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893023000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893023000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:57:01Z","timestamp":1714690621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893023000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1323893023000503"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2023.06.001","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}